437 related articles for article (PubMed ID: 34922844)
21. Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".
Kesireddy M; Lunning M
Oncology (Williston Park); 2022 Jun; 36(6):366-375. PubMed ID: 35723942
[TBL] [Abstract][Full Text] [Related]
22. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
23. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
24. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
Atallah-Yunes SA; Robertson MJ; Davé UP; Ghione P; Perna F
Front Immunol; 2022; 13():901365. PubMed ID: 35720352
[TBL] [Abstract][Full Text] [Related]
25. [CAR-T therapy for malignant lymphoma].
Shimoyama T
Rinsho Ketsueki; 2023; 64(11):1447-1455. PubMed ID: 38072433
[TBL] [Abstract][Full Text] [Related]
26. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
29. [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
Bücklein V; von Tresckow B; Subklewe M
Dtsch Med Wochenschr; 2024 May; 149(11):630-637. PubMed ID: 38749439
[TBL] [Abstract][Full Text] [Related]
30. The value of bispecific antibodies in relapsed and refractory DLBCL.
Lewis KL; Cheah CY
Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
[TBL] [Abstract][Full Text] [Related]
31. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
32. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
Major A; Kamdar M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):370-381. PubMed ID: 38066907
[TBL] [Abstract][Full Text] [Related]
33. [Current and future perspectives on CAR-T cell therapy to adult malignant lymphoma].
Shimoyama T
Rinsho Ketsueki; 2023; 64(9):1192-1202. PubMed ID: 37899200
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
Gong IY; Aminilari M; Landego I; Hueniken K; Zhou Q; Kuruvilla J; Hodgson DC
Leuk Lymphoma; 2023 Oct; 64(10):1643-1654. PubMed ID: 37548344
[TBL] [Abstract][Full Text] [Related]
35. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
[TBL] [Abstract][Full Text] [Related]
36. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
38. Immune-based therapies in diffuse large B-cell lymphoma.
McCurry D; Flowers CR; Bermack C
Expert Opin Investig Drugs; 2023; 32(6):479-493. PubMed ID: 37394970
[TBL] [Abstract][Full Text] [Related]
39. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
40. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.
Perrone S; Lopedote P; Levis M; Di Rocco A; Smith SD
Expert Rev Hematol; 2022 Mar; 15(3):215-232. PubMed ID: 35184664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]